Citations

Clear

16280 citation(s) found for "Yu, David".

Survival benefit associated with liver transplantation for hepatocellular carcinoma based on tumor burden scores at listing
Liu, Hao , Lee, Hang , Shi, Liuhua , Wang, Xixi , Powers, Colin , Li, Xingjie , Alberola, Ramon Bataller, Behari, Jaideep , Duarte‐Rojo, Andrés , Hughes, Dempsey L. , Malik, Shahid M. , Jonassaint, Naudia , Tohme, Samer , Gunabushanam, Vikraman , Tevar, Amit D. , Cruz, Ruy J. , Dharmayan, Stalin, Ayloo, Subhashini, Humar, Abhinav , Liu, Hao , Duarte-Rojo, Andres , Zhang, Wei , Di, Mengyang , Wang, Xixi, Zhang, Xingyu , Sethi, Vrishketan , Xiao, Yao , Crane, Andrew, Kaltenmeier, Christof , Geller, David A. , Hughes, Christopher L. , Molinari, Michele

Mayo Clinic

Hepatology Communications | January 7, 2025 | Volume: 9 | Issue: 1 | Pages: No page available

10.1097/hc9.0000000000000619 | PMID 39774957 Get It

Introduction: Liver transplantation (LT) provides significant survival benefits to patients with unresectable HCC. In the United States, organ allocation policies for HCCs within the United Network for Organ Sharing criteria do not prioritize patients based on their differences in oncological characteristics. This study assessed whether transplant-associated survival benefits (TASBs) vary among patients with different tumor burden scores (TBS) measured at the time of listing. Methods: We analyzed data from adults applying for HCC MELD exception points between 2002 and 2019, with follow-up until December 2023, using the Scientific Registry of Transplant Recipients. TBS was determined based on the largest tumor diameter and number of HCCs. Patients were categorized into low (≤3), intermediate (3.1–5), and high (>5) TBS groups. TASB was measured as the difference in 5-year survival with and without LT. Results: This study included 36,634 LT candidates. High-TBS patients had higher waitlist dropout rates and marginally lower post-transplant survival, resulting in a significantly greater TASB. The 5-year TASB for the low, intermediate, and high TBS groups were 15.7, 22.1, and 25.0 months, respectively. The adjusted survival benefit expressed in 5-year survival differences was 21.9%, 34.5%, and 39.4% in the low, intermediate, and high TBS groups, respectively ( p <0.001). Conclusions: Higher TBS during listing correlates with greater LT benefits for patients with unresectable HCC within UNOS criteria. We conclude that organ allocation policies in the United States should prioritize patients with high TBS due to their increased risk of dropout and comparable post-transplant survival when compared to patients with less advanced tumors.
The assessment of point-of-care ultrasound (POCUS) in residency: the benefits of a four-year longitudinally integrated curriculum
Le, David , Scarpulla, Megan, Kern, Julia, Vroegop, Spencer, Yaeger, Jordan, Finch, Charles, Martini, Wayne A , Al‐Nakkash, Layla , Martini, Wayne, Lam, Hubert, Yaeger, Jordan , Bolch, Charlotte

Mayo Clinic

Journal of Osteopathic Medicine | January 7, 2025 | Volume: 125 | Issue: 3 | Pages: 119-126

10.1515/jom-2024-0046 | PMID 39764717 Get It

Abstract Context Point-of-care ultrasound (POCUS) has diverse applications across various clinical specialties, serving as an adjunct to clinical findings and as a tool for increasing the quality of patient care. Owing to its multifunctionality, a growing number of medical schools are increasingly incorporating POCUS training into their curriculum, some offering hands-on training during the first 2 years of didactics and others utilizing a longitudinal exposure model integrated into all 4 years of medical school education. Midwestern University Arizona College of Osteopathic Medicine (MWU-AZCOM) adopted a 4-year longitudinal approach to include POCUS education in 2017. There is a small body of published research supporting this educational model, but there is not much data regarding how this approach with ultrasound curriculum translates to real-world changes in POCUS use by graduate student clinicians having received this model of education. Objectives The objectives of this study are to determine the frequency of POCUS use by MWU-AZCOM graduates and to assess how a 4-year longitudinal ultrasound curriculum may enhance the abilities of MWU-AZCOM graduates to perform and interpret ultrasound imaging in specific residency programs. Methods The study was approved by the MWU Institutional Review Board (#IRBAZ-5169, approval date October 3, 2022). An anonymous novel 12-question survey was conducted utilizing Research Electronic Data Capture (REDCap), a secure online platform, and distributed to MWU-AZCOM 2021 and 2022 graduates via email. Survey questions were aimed at assessing frequency of use, utilization of different imaging modalities, reasons for utilizing POCUS, barriers/enablers to utilizing POCUS, ultrasound training, and confidence in performing scans and interpreting POCUS imaging. All of the 104 surveys returned were included in the study. Statistical software R version 4.3 was utilized to conduct statistical analyses. Results Of the 484 surveys distributed, 104 were completed (21.5 % response rate). Responses came from residents working in 14 different specialties, 50 in primary care and 54 in nonprimary care. Of all respondents, 85.6 % currently utilize POCUS in their practice on at least a monthly basis and 77.0 % believe that their POCUS training in medical school enriches their current practice in residency. The top five modalities utilized by residents were procedures (89.9 %), cardiac (88.8 %), pulmonary (82.0 %), Focused Assessment with Sonography for Trauma (FAST, 73.0 %), and vascular (71.9 %). Respondents recognized POCUS as a beneficial diagnostic tool (97.8 %) and reported enhancements in physical examination skills (58.4 %) and professional growth (61.8 %). Facilitators for POCUS adoption included cost-effectiveness (82.0 %), diagnostic differentiation (78.7 %), and safety (79.8 %). Barriers included a lack of trained faculty (27.9 %), absence of necessary equipment (26.9 %), and cost of equipment (22.1 %). Participants demonstrated high confidence levels in performing (74.0 %) and interpreting (76.0 %) POCUS, with 43.3 % believing that their POCUS training enhanced their attractiveness as residency candidates. Conclusions This study supports the positive impact of a 4-year longitudinal POCUS curriculum on graduates’ practice. It emphasizes the link between MWU-AZCOM’s curriculum and real-world clinical needs. Addressing identified barriers and advancing hands-on training can further enhance POCUS understanding, ensuring that future physicians are well-prepared to leverage its diagnostic potential across medical specialties.
The Impact of “Close Margins” in HPV‐Associated Oropharyngeal Squamous Cell Carcinoma Treated With TORS
Calcano, Gabriela A. , Rourk, Katelyn S. , O’Byrne, Jamie, García, Joaquín J. , Tasche, Kendall K. , Moore, Eric J. , Abel, Kathryn M. Van , O'Byrne, Jamie J, Van Abel, Kathryn M , Yin, Linda X , Routman, David M. , Chintakuntlawar, Ashish V. , Price, Daniel L. , Yin, Linda X.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | January 7, 2025 | Volume: 172 | Issue: 4 | Pages: 1291-1299

10.1002/ohn.1127 | PMID 39764676 Get It

Abstract Objective Margin distance is a significant prognosticator in oral cavity cancer but its role in HPV‐related oropharyngeal squamous cell carcinoma [HPV(+)OPSCC] remains unclear. Here, we investigate the impact of margin distance on locoregional recurrence in HPV(+)OPSCC. Study Design This is a retrospective cohort study of surgically treated HPV(+)OPSCC patients. Patients received either standard of care (at least 60 Gy with or without cisplatin) or de‐escalated adjuvant therapy (30‐36 Gy with concurrent docetaxel). Margin distance was measured in mm from the primary specimen or in combination with separately submitted margins. Kaplan‐Meier survival analysis with univariate and multivariable Cox regressions were conducted to determine the impact of margin distance on risk of local and locoregional recurrence. Setting Setting for this is 3 tertiary centers between January 2010 and February 2024. Results Among 1102 included patients, 33 (3.0%) had positive final margins. 374 patients had adequate margin distance data available. Margin distance was >3 mm in 73.4%, 1 to 3 mm in 24.5%, and <1 mm in 2.2% of patients. Positive final margins, pT4 disease, pN2 disease, and surgery alone as a treatment modality ( P < .02 for all) was associated with higher risk of 5‐year locoregional recurrence. Margin distance did not significantly impact risk of local or locoregional recurrence even after adjusting for de‐escalated adjuvant therapy ( P > .05). Conclusion Positive final margins after TORS without adjuvant radiotherapy for HPV(+)OPSCC carries a high risk of local recurrence. Margin distance does not appear to significantly impact risk of local or locoregional recurrence, even after de‐escalated adjuvant radiotherapy.
Correlation of the Sinonasal Outcome Test‐22 With the University of Washington Quality of Life in Assessing Quality of Life in Sinonasal Malignancy Utilizing a Multicenter Prospective Observational Cohort Registry
Fleseriu, Cara M. , Beswick, Daniel M. , Maoz, Sabrina L. , Hwang, Peter H. , Adappa, Nithin D. , Getz, Anne E., Humphreys, Ian M. , Traylor, Katie , Chang, Eugene H. , Jafari, Aria , Kingdom, Todd T. , Kohanski, Michael A. , Lee, Jivianne K., Patel, Zara M. , Smith, Timothy L. , Wang, Marilene B. , Wang, Eric W , Beswick, Daniel , Maoz, Sabrina L , Hwang, Peter H , Humphreys, Ian M , Jafari, Aria , Kingdom, Todd T , Nayak, Jayakar V , Patel, Zara , Smith, Timothy L , Snyderman, Carl H , Choby, Garret , Kuan, Edward C , Adappa, Nithin D. , Geltzeiler, Mathew , Abuzeid, Waleed M. , Pinheiro‐Neto, Carlos , Le, Christopher H. , Lee, Jivianne K., Nayak, Jayakar V. , John, Maie A. St. , Suh, Jeffrey D. , Choby, Garret

Mayo Clinic

International Forum of Allergy & Rhinology | January 6, 2025 | Volume: 15 | Issue: 4 | Pages: 451-454

10.1002/alr.23522 | PMID 39761380 Get It

Glucarpidase for treatment of high-dose methotrexate toxicity
Gupta, Shruti , Kaunfer, Sarah Allison , Chen, Kevin L. , Dias, Julie‐Alexia , Rajasekaran, Arun , Prosek, Jason, Truong, Huong L. , Wood, Anthony C., Bassil, Claude , Renaghan, Amanda D., Carlos, Christopher A., Kelly, Katherine J. , Passero, Christopher J., Abudayyeh, Ala , Shin, Daniel Sanghoon , Yelvington, Bradley, Kanduri, Swetha Rani , Neyra, Javier A. , Shirali, Anushree C. , Bansal, Anip, Geara, Abdallah Sassine , Mithani, Zain, Ziolkowski, Susan , Rashidi, Arash, Jakubowski, Jonathan, Pujari, Ashwini, Dotson, Emily, Wall, Sarah , Patton, John T. , Barreto, Jason N. , Sheikh, M. Salman , Lee, Jamie, Lucchesi, Nicholas, Kolman, Michael David, Rasheed, Muhammad Ahsan, Afzal, Afsheen, Mahesh, Amrita, Hsu, Raymond K. , Nicolaysen, Anthony, Tefera, Kibrewessen, Schretlen, Claire F. , Miller, Ryan M. , Velez, Juan Carlos Q. , Chandrasekhara, Soniya, Donley, Vicki, Patel, Ashka , Krishnamurthy, Shobana, Ali, Rafia, Yilmam, Osman A , Wells, Sophia L., Ortega, Jessica L. , Green‐Lingren, Olivia, Leaf, Rebecca Karp , Sise, Meghan E. , Nayak, Lakshmi , LaCasce, Ann S. , Leaf, David E. , Kaunfer, Sarah A , Rajasekaran, Arun , Shah, Chintan V , Glezerman, Ilya G , Kelly, Katherine , Abudayyeh, Ala , Neyra, Javier A , Edmonston, Daniel , Ziolkowski, Susan L , Bond, David A , Patton, John , Barreto, Jason N , Herrmann, Sandra M , Sheikh, Mohammad S , Hsu, Raymond K , Aklilu, Abinet M , Krishnamurthy, Shobana , Yilmam, Osman A , Ortega, Jessica L , LaCasce, Ann Steward , Leung, Nelson , Leaf, David E , Gupta, Shruti , Dias, Julie-Alexia , Vijayan, Anitha , Zhang, Jingjing , Drappatz, Jan , Sperati, Christopher John , Rashidi, Arash , Bond, David A. , Patton, John T. , Herrmann, Sandra M. , Baz, Rachid , Lee, Jamie, Kolman, M F , Afzal, Afsheen, Kang, Dasol, Mahesh, Amrita, Miller, Ryan M., Flannery, Alexander H , Aklilu, Abinet M. , Anand, Shuchi , Ni, Jian, Wells, Sophia L., Leung, Nelson

Mayo Clinic

Blood | January 6, 2025 | Volume: 145 | Issue: 17 | Pages: 1858-1869

10.1182/blood.2024026211 | PMID 39760780 Get It

Abstract High-dose methotrexate (MTX) results in high rates of acute kidney injury (AKI), neutropenia, and hepatotoxicity. Glucarpidase is a recombinant enzyme that cleaves MTX, but clinical data supporting its use are scarce. We examined the association between glucarpidase administration and outcomes in adults with MTX-AKI from 28 cancer centers across the United States using a sequential target trial emulation framework. The primary end point was kidney recovery at hospital discharge, defined as survival to discharge with serum creatinine &lt;1.5-fold baseline and without dialysis dependence. Key secondary end points were time to kidney recovery, neutropenia, and transaminitis on day 7, and time to death. Using multivariable logistic and Cox regression models, we compared outcomes in patients who received glucarpidase within 4 days following MTX initiation with those in patients who did not. Among 708 patients with MTX-AKI, 209 (29.5%) received glucarpidase. Overall, 183 (25.8%) had a primary end point event. Glucarpidase receipt was associated with a 2.70-fold higher adjusted odds of kidney recovery (95% confidence interval [CI], 1.69–4.31) compared with no glucarpidase receipt. Patients treated with glucarpidase also had faster time to kidney recovery (adjusted hazard ratio [aHR], 1.88; 95% CI, 1.18–3.33) and lower risks of grade ≥2 neutropenia (adjusted odds ratio [aOR], 0.50; 95% CI, 0.28–0.91) and grade ≥2 transaminitis (aOR, 0.50; 95% CI, 0.28–0.91) on day 7. There was no difference in time to death (aHR, 0.76; 95% CI, 0.49–1.18). These data suggest glucarpidase may improve both renal and extrarenal outcomes in patients with MTX-AKI.
Prevalence and Risk Factors of Spondyloarthritis Symptoms in a US-Based Multicenter Cohort of Patients With Inflammatory Bowel Disease
Hong, Simon , Dalal, Rahul S. , Kuhn, Kristine A. , Stahly, Andrew , Scott, Frank I. , Click, Benjamin , Way, Anna, Malik, Fardina , Davis, John M. , Shmais, Manar , Raffals, Laura E., Silfen, Alexa , Dharia, Ishaan , Bhattacharya, Ashish K. , Moghaddam, Bahar, Mains, Trayton, Kurland, Jayde E., Hong, Simon J , Click, Benjamin H , Rubin, David T , Bhattacharya, Abhik , Ermann, Joerg , Jan, Reem , Davis, John M , Silfen, Alexa , Kuhn, Kristine A , Scott, Frank I , Way, Anna, Raffals, Laura E. , Rubin, David T. , Patel, Sheena , Weisman, Michael H. , Ermann, Joerg

Mayo Clinic

American Journal of Gastroenterology | January 6, 2025 | Volume: 120 | Issue: 10 | Pages: 2330-2338

10.14309/ajg.0000000000003292 | PMID 39760386 Get It

INTRODUCTION: Spondyloarthritis (SpA), the most common extraintestinal manifestation of inflammatory bowel disease (IBD), is reported in up to 39% of patients with IBD. Despite this high prevalence, risk factors of developing SpA in patients with IBD are not well described. In this study, we aimed to determine the factors associated with SpA symptoms and their prevalence in an IBD cohort. METHODS: Two validated screening questionnaires for the detection of SpA in IBD (DETAIL = DETection of Arthritis in Inflammatory boweL diseases, IBIS-Q = IBD Identification of Spondyloarthritis Questionnaire) were administered to patients with IBD without a prior diagnosis of SpA in 6 US academic medical centers. Demographic data, IBD characteristics, and medication history were recorded. RESULTS: Screening questionnaires were completed by 588 patients (220 ulcerative colitis, 349 Crohn's disease, and 19 IBD-unclassified), with a median age of 40 years (interquartile range 30–53) and median disease duration of 12 years (interquartile range 6–22). The number of positive screens was 130 (22%) for DETAIL, 196 (33%) for IBIS-Q, and 204 (35%) for either DETAIL or IBIS-Q. Age, female sex, history of smoking, prior bowel surgery, and history of any biologic or targeted small molecule exposure were associated with a positive screen on univariate analysis. After multivariate analysis, female sex (odds ratio [OR] 2.03, 95% confidence interval [CI] 1.41–2.93), older age (OR 1.02, 95% CI 1.01–1.04), history of smoking (OR 1.67, 95% CI 1.04–2.69), and history of any biologic or targeted small molecule exposure (OR 2.27, 95% CI 1.34–3.84) were independently associated with positive screens. Higher number of biologic exposures was associated with higher risk of positive screens, with the highest risk seen with 3 or more exposures (OR 3.25, 95% CI 1.75–6.03). DISCUSSION: A substantial number of patients with IBD screen positive for SpA symptoms, indicating a potentially high burden of undiagnosed illness. Factors associated with SpA symptoms include older age, female sex, and more severe disease (based on increased number of advanced therapies or prior surgery), whereas IBD phenotype does not independently increase the risk of a positive SpA screen. Further studies are needed to confirm these findings and better characterize SpA in IBD.
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitors
Ambrosini, Margherita , Alouani, Emily , Lonardi, Sara , Hafliger, Émilie , Mazard, Thibault , Pernot, Simon , Parent, Pauline , Ros, Javier , Overman, Michael J. , Guimbaud, Rosine , Cremolini, Chiara , Taieb, Julien , Ambrosini, Margherita , Lonardi, Sara , Overman, Michael J , Tougeron, David , Pietrantonio, Filippo , Cremolini, Chiara , Taı̈eb, Julien , Sinicrope, Frank A. , Decraecker, Marie , Boilève, Alice , Jayachandran, Priya , Nasca, Vincenzo , Salvatore, Lisa , Tougeron, David , Pietrantonio, Filippo

Mayo Clinic

Journal for ImmunoTherapy of Cancer | January 6, 2025 | Volume: 13 | Issue: 1 | Pages: e010424

10.1136/jitc-2024-010424 | PMID 39755579 Get It

Background Immune checkpoint inhibitors (ICIs) are recommended to treat patients with deficient mismatch repair/microsatellite instability high (dMMR/MSI-H) metastatic colorectal cancer (mCRC). Pivotal trials have fixed a maximum ICI duration of 2 years, without a compelling rationale. A shorter treatment duration has the potential to improve patients' quality of life and reduce both toxicity and cost without compromising efficacy. Here we examine whether early treatment discontinuation (ETD) before 13 months in patients without progressive disease (PD) can lead to similar long-term disease control compared with a longer treatment duration (LTD). Methods To assess whether ETD is associated with similar outcomes compared with LTD, we assembled an international cohort of patients with dMMR/MSI-H mCRC treated with ICIs who stopped treatment for a reason other than PD within 395 days (ETD group) and compared them to those who continued for >395 days (LTD group). Outcomes were adjusted for patient/tumor characteristics. Primary endpoint was progression-free survival (PFS) and secondary endpoints were objective response rate (ORR), overall survival (OS) and safety. Results Of 976 patients, 137 and 394 were allocated to the ETD and LTD groups, respectively. In the ETD group, treatment was discontinued due to toxicity (n=56), objective response (n=43), surgery (n=28), patient decision (n=2) or other reasons (n=8). Baseline characteristics were well balanced between the two groups: 22% in both groups received both anti-programmed death-(ligand) 1 (anti-PD-(L)1) + anti-cytotoxic T-lymphocyte antigen-4 (anti-CTLA-4); all others received anti-PD-(L)1 monotherapy. ORR to ICIs was 81% in both groups. Median duration of treatment was ~7 months in the ETD and ~24 months in the LTD group. After a median follow-up of 44 months (IQR: 30–67), similar PFS (HR: 0.92, 95% CI: 0.60 to 1.40, p=0.69) and OS (HR: 1.15, 95% CI: 0.66 to 1.99, p=0.62) from the start of ICIs were observed in ETD and LTD patients. In the ETD group, 28 (20%) patients had a PFS event and 9 restarted ICIs with a disease control rate of 66%. Conclusions In our international series of dMMR/MSI-H mCRC, ETD of ICIs in the absence of PD did not seem detrimental in terms of PFS and OS compared with continuing treatment beyond 1 year. Randomized clinical trials to compare short and long treatment duration are now warranted.
Solving climate change requires changing our food systems
Feigin, Svetlana , Wiebers, David O. , Blumstein, Daniel T. , Knight, Andrew , Eshel, Gidon , Lueddeke, George R., Kopnina, Helen , Brainin, Michael, Alexander, Shelley M., Merskin, Debra , Kleef, Gerben A. van , Freeman, Carrie Packwood , Feigin, Valery L. , Morand, Sergé , Lee, Kelley , Shackelford, Todd K. , Marcum, James A. , Skerratt, Lee Francis , Whitfort, Amanda S. , Winkler, Andrea Sylvia

Mayo Clinic

Oxford Open Climate Change | January 3, 2025 | Volume: 5 | Issue: 1 | Pages: No page available

10.1093/oxfclm/kgae024 Get It

Abstract Humanity is facing an important existential threat—irreversible climate change caused by human activity. Until recently, most of the proposals to address climate change have downplayed or ignored the adverse impact of food systems, especially intensive animal agriculture. This is in spite of the fact that up to a third of global greenhouse gas production to date can be attributed to animal agriculture. Recent developments at COP28 have signaled that the tide is turning, however, and that food systems are becoming part of global discussions on climate change solutions. The pressing nature of irreversible climate change requires rethinking our food systems. To solve the climate change crisis, we propose transitioning to a predominantly plant-based diet, and phasing out intensive animal agriculture as diets shift, without increasing pastoral farming. We suggest that such transformations in global food systems can be accomplished largely through education and large-scale public information campaigns, removal of subsidies, taxation to account for externalized costs of animal agriculture, improved labelling of products, and various investment/divestment drivers. Better metrics and industry benchmarks involving food and agriculture-specific performance indicators that reflect food system sustainability will be important. Increased global awareness of these issues and a change in mindset (which will drive political will) also are needed. Our current trajectory is untenable, and we must begin to turn the ship now towards sustainable food systems and diets.
Integrating Pharmacogenomics into the Broader Construct of Genomic Medicine: Efforts by the ClinGen Pharmacogenomics Working Group (PGxWG)
Gong, Li , Klein, Clarissa , Caudle, Kelly E. , Moyer, Ann M. , Klein, Teri E. , (PGxWG), ClinGen Pharmacogenomics Working Group, Ashcraft, Kristine , Bernhardt, Brooke, Blaxwell, Burns C, Bly, Zo, Cody, Neal, Tredici, Andria L. Del , Gregornik, David , Hart, Jennifer, Hoffman, James M. , Landrum, Melissa , Langlais, Kristofor K., Lee, M T M, Li, Rongling, McLeod, Howard L. , Monte, Andrew A. , Naik, Hetanshi , Obeng, Aniwaa Owusu , Ramos, Erin M. , Ren, Zhaoxia , Ritchie, Marylyn D. , Scherer, Steven E. , Shaaban, Sherin, Swen, Jesse J. , McIntyre, Joanne, Merritt, Keren, Wright, Matt W. , Klein, Teri E , Scott, Stuart A. , Whirl‐Carrillo, Michelle , (PGxWG), ClinGen Pharmacogenomics Working Group, Aminkeng, Folefac , Amr, Sami S , Cipriani, Amber , Dandara, Collet , Empey, Philip E. , Fieg, Elizabeth L. , Gaedigk, Andrea , Harrison, Steven M. , Hunter, Jessica Ezzell , Iwuchukwu, Otito Frances , Malheiro, Adriana , Morales, Joannella , Oni‐Orisan, Akinyemi , Rogers, Sara , Wagner, Alex H. , Woodahl, Erica L , McIntyre, Joanne, Merritt, Keren

Mayo Clinic

Clinical Chemistry | January 3, 2025 | Volume: 71 | Issue: 1 | Pages: 36-44

10.1093/clinchem/hvae181 | PMID 39749515 Get It

Abstract Pharmacogenomics (PGx) is focused on the relationship between an individual's genetic makeup and their response to medications, with the overarching aim of guiding prescribing decisions to improve drug efficacy and reduce adverse events. The PGx and genomic medicine communities have worked independently for over 2 decades, developing separate standards and terminology, making implementation of PGx across all areas of genomic medicine difficult. To address this issue, the Clinical Genome Resource (ClinGen) Pharmacogenomics Working Group (PGxWG) was established by the National Institutes of Health (NIH)-funded ClinGen to initially create frameworks for evaluating gene–drug response clinical validity and actionability aligned with the ClinGen frameworks for evaluating monogenic gene–disease relationships, and a framework for classifying germline PGx variants similar to the American College of Medical Genetics (ACMG) and Association of Molecular Pathology (AMP) system for interpretation of disease-causing variants. These frameworks will leverage decades of work from well-established PGx resources facilitating buy-in among PGx stakeholders. In this report, we describe the background and major activities of the ClinGen PGxWG, and how this initiative will facilitate the critical inclusion of PGx into the larger context of genomic medicine.
Clinical Genomics: Current and Emerging Trends
Lockwood, Christina M. , Mason‐Suares, Heather , Moyer, Ann M. , Spencer, David H. , Roychoudhury, Pavitra

Mayo Clinic

Clinical Chemistry | January 3, 2025 | Volume: 71 | Issue: 1 | Pages: 1-3

10.1093/clinchem/hvae191 Get It